Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.68 |
| ▸ | PDE4A | P27815 | 11/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.68 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887789 | 1.00 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL5875876 | 0.89 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL2888335 | 0.89 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6489896 | 0.87 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6479899 | 0.86 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6479903 | 0.84 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6485190 | 0.84 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL5553386 | 0.84 | PDE4D (0.78) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6485199 | 0.84 | PDE4D (0.71) | PDE4DPDE4BPDE4APDE4CPDE7B | |
| SCHEMBL6256486 | 0.83 | PDE7B (0.85) | PDE4DPDE4BPDE4APDE4CPDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | claimed |
| WO-2004098578-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A TNF-ALFA ANTAGONIST SELECTED FROM INFLIXIMAB, ADALIMUMAB, CDP870 AND CDP517 | ALTANA PHARMA AG (DE) | 2004-11-18 | — | — | WO | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | disclosed |